Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | PPIB | P23284 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | PPIG | Q13427 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL27932714 | 0.85 | NPC1 (0.62) | CNR2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL826024 | 0.84 | HPGD (0.51) | HPGDKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL13255794 | 0.82 | HPGD (0.69) | HPGDKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL31344791 | 0.82 | HPGD (0.50) | HPGDKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL18868428 | 0.82 | ALDH1A1 (0.61) | KMT2ALMNAALDH1A1MEN1NPC1 | |
| SCHEMBL24474317 | 0.82 | HPGD (0.50) | HPGDKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL2451676 | 0.82 | ESRRB (0.55) | HPGDLMNANPC1RAB9AKDM4E | |
| SCHEMBL8269170 | 0.81 | ALDH1A1 (0.44) | HPGDCNR2KMT2ALMNAALDH1A1 | |
| SCHEMBL9499789 | 0.81 | HPGD (0.46) | HPGDKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL21185332 | 0.81 | HPGD (0.49) | HPGDKMT2ALMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2025-11-18 | — | — | US | disclosed |
| CN-117534670-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3697784-B9 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-12-27 | — | — | EP | disclosed |
| CN-111225916-B | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4265254-A2 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265254-A2 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| EP-3697784-B1 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-04 | — | — | EP | disclosed |
| US-7956219-B2 | Amino acid analogues | Baker IDI Heart and Diabetes (AU) | 2011-06-07 | — | — | US | disclosed |
| US-7569570-B2 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7300935-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1591446-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1479684-A1 | THIENOPYRIMIDINES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
| EP-0374661-A1 | Reactive dyes | BAYER AG (DE) | 1990-06-27 | — | — | EP | disclosed |
| EP-0371332-A1 | Reactive dyes | BAYER AG (DE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | HPGD 3258/4885CNR2 423/4885KMT2A 227/4885 |
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | GNRHR, CRH, CYP19A1 | HPGD 2397/4885CNR2 1565/4885KMT2A 2131/4885 |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL15, IL2, IL33 | HPGD 849/4885CNR2 193/4885KMT2A 3843/4885 |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | HPGD 849/4885CNR2 193/4885KMT2A 3843/4885 |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | HPGD 3258/4885CNR2 423/4885KMT2A 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.